Valenti Alessandro, Falcone Italia, Valenti Fabio, Ricciardi Elena, Di Martino Simona, Maccallini Maria Teresa, Cerro Marianna, Desiderio Flora, Miseo Ludovica, Russillo Michelangelo, Guerrisi Antonino
Radiology and Diagnostic Imaging Unit, Department of Clinical and Dermatological Research, San Gallicano Dermatological Institute IRCCS, 00144 Rome, Italy.
SAFU, Department of Research, Advanced Diagnostics, and Technological Innovation, IRCCS-Regina Elena National Cancer Institute, 00144 Rome, Italy.
J Pers Med. 2024 Jul 6;14(7):731. doi: 10.3390/jpm14070731.
In recent years, medicine has undergone profound changes, strongly entering a new phase defined as the "era of precision medicine". In this context, patient clinical management involves various scientific approaches that allow for a comprehensive pathology evaluation: from preventive processes (where applicable) to genetic and diagnostic studies. In this scenario, biobanks play an important role and, over the years, have gained increasing prestige, moving from small deposits to large collections of samples of various natures. Disease-oriented biobanks are rapidly developing as they provide useful information for the management of complex diseases, such as melanoma. Indeed, melanoma, given its highly heterogeneous characteristics, is one of the oncologic diseases with the greatest clinical and therapeutic management complexity. So, the possibility of extrapolating tissue, genetic and imaging data from dedicated biobanks could result in more selective study approaches. In this review, we specifically analyze the several biobank types to evaluate their role in technology development, patient monitoring and research of new biomarkers, especially in the melanoma context.
近年来，医学发生了深刻变革，强势迈入被定义为“精准医学时代”的新阶段。在此背景下，患者的临床管理涉及多种科学方法，可对病理学进行全面评估：从（适用时的）预防流程到基因和诊断研究。在这种情况下，生物样本库发挥着重要作用，多年来其声望与日俱增，从小型存储库发展到各类性质样本的大型集合。以疾病为导向的生物样本库正在迅速发展，因为它们为黑色素瘤等复杂疾病的管理提供了有用信息。事实上，黑色素瘤因其高度异质性特征，是临床和治疗管理最为复杂的肿瘤疾病之一。因此，从专门的生物样本库中推断组织、基因和影像数据的可能性可能会带来更具选择性的研究方法。在本综述中，我们专门分析了几种类型的生物样本库，以评估它们在技术发展、患者监测和新生物标志物研究中的作用，尤其是在黑色素瘤背景下。
